Most patients experience no interruption in treatment
In two phase 3 clinical trials, retatrutide, a novel glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP-1), and glucagon triple-hormone receptor agonist, demonstrated significant weight loss and clinically meaningful improvements in health outcomes in people living with obesity and type 2 diabetes
Both medications cause similar side effects, mostly gastrointestinal, such as nausea, vomiting, diarrhea, and constipation
It delivers a comprehensive blend of key vitamins and mineralsincluding iron, vitamin B-12, thiamin, and magnesiumto help support overall wellness and aid in the prevention of deficiencies associated with reduced nutrient intake, such as anemia, fatigue, and hair loss
However, further validation in larger and more diverse patient populations is recommended to strengthen generalizability
As a standard GLP-1 analog, semaglutide 10mg serves as a vital control or baseline in many metabolic experiments
